| Project/Area Number |
23591821
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
HIDAKA Isao 山口大学, 医学部附属病院, 助教 (70593440)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMASAKI Takahiro 山口大学, 大学院医学系研究科, 教授 (00304478)
UCHIDA Koichi 山口大学, 医学部附属病院, 講師 (80397992)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 肝動注化学療法 / 肝細胞癌 / 微小デンプン球 / ミリプラチン / VEGF |
|---|
| Research Abstract |
We designed a novel transcatheter arterial infusion chemotherapy as transvascular treatment for hepatocellular carcinoma, without the use of a solid embolic material, and the use of lipiodol and degradable starch microspheres (DSM). We investigated the efficancy of this therapy using cisplatin in clinical trial. In this study, we examined the usefulness of this new hepatic arterial infusion chemotherapy using miriplatin affinity with lipiodol better than cisplatin. In 2011, we start a prospective randomized study by two groups (DSM non-combination group, DSM combination group). So far, we treated in 30 cases. At the moment, progression-free survival tend to extended in DSM combination group, andresponse rate to be high in DSM combination group. We think this treatment is useful as a new hepatic arterial infusion chemotherapy.
|
